Quantum Biopharma (QNTM) EBITDA (2019 - 2026)

Quantum Biopharma has disclosed EBITDA across 8 years of filings, most recently posting -$13.6 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$13.6 million, down 55.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$30.3 million (down 72.55% YoY), and the FY2025 annual result was -$15.3 million, up 5.17% from the prior year.
• EBITDA came in at -$13.6 million for Q1 2026 at Quantum Biopharma, down from -$2.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $25.3 million in Q2 2023 to a low of -$13.6 million in Q1 2026.
• The 5-year median for EBITDA is -$3.4 million (2024), against an average of -$2.6 million.
• Peak annual rise in EBITDA reached 76.62% in 2024, while the deepest fall reached 278.05% in 2024.
• Quantum Biopharma's EBITDA stood at $6.0 million in 2022, then tumbled by 220.6% to -$7.2 million in 2023, then soared by 70.99% to -$2.1 million in 2024, then declined by 13.48% to -$2.4 million in 2025, then plunged by 474.31% to -$13.6 million in 2026.
• The last three EBITDA figures came in at -$13.6 million (Q1 2026), -$2.4 million (Q4 2025), and -$4.6 million (Q3 2025), per Business Quant data.